Telix Pharmaceuticals Stock Price, News & Analysis (ASX:TLX) Add Compare Share Share Today's Range N/A50-Day RangeA$41.24▼A$49.9252-Week Range N/AVolume746,789 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A About Telix Pharmaceuticals Stock (ASX:TLX)Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.Read More TLX Stock News HeadlinesDecember 4, 2023 | finance.yahoo.comFirst Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging AgentNovember 29, 2023 | finanznachrichten.deTelix Pharmaceuticals Limited: Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCSDecember 6, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 29, 2023 | finance.yahoo.comPhase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCSNovember 22, 2023 | fool.com.auCould buying these ASX shares at $9 now be like investing in Tesla in 2010?November 14, 2023 | finance.yahoo.comQSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option FeeNovember 13, 2023 | finanznachrichten.deTelix Pharmaceuticals Limited: Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®November 13, 2023 | finance.yahoo.comMauna Kea Technologies and Telix Pharmaceuticals to Expand Partnership in Uro-oncologic SurgeryDecember 6, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. November 13, 2023 | finance.yahoo.comTelix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology SurgeryNovember 8, 2023 | finance.yahoo.comTelix to Present at Jefferies London Healthcare Conference 2023October 19, 2023 | fool.com.auTelix Pharmaceuticals share price sinks 12% despite rocketing revenueOctober 18, 2023 | finanznachrichten.deTelix Pharmaceuticals Limited: ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and TolerabilityOctober 18, 2023 | finance.yahoo.comTelix reports fourth consecutive quarter of positive operating cash flowOctober 17, 2023 | msn.comGlobal biotech sector set to boom but where are Aussie investors?September 19, 2023 | fool.com.auWho wants to be a millionaire? 3 ASX shares I think that could make it happenSeptember 19, 2023 | fool.com.auWho wants to be a millionaire? 3 ASX shares I think could make it happenAugust 24, 2023 | fool.com.auASX 200 healthcare stock Telix Pharmaceuticals surges 12% on ‘excellent result’August 23, 2023 | finanznachrichten.deTelix Pharmaceuticals Limited: Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage CompanyJuly 19, 2023 | fool.com.auWhy is the Telix share price crashing 17% today?July 19, 2023 | finance.yahoo.comTelix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash FlowJune 26, 2023 | finanznachrichten.deTelix Pharmaceuticals Limited: New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCCJune 22, 2023 | reuters.comAustralia's Telix Pharma hits record high after buying UK medical devices firmJune 22, 2023 | finance.yahoo.comTelix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMIJune 21, 2023 | finanznachrichten.deTelix Pharmaceuticals Limited: Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint MedicalJune 21, 2023 | finance.yahoo.comTelix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint MedicalJune 20, 2023 | finanznachrichten.deTelix Pharmaceuticals Limited: Telix Urology Innovation Showcase to be held at The Yale Club, New York CitySee More Headlines Receive TLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:TLX CUSIPN/A CIKN/A Webwww.telixpharma.com Phone61 4 4914 8448FaxN/AEmployees234Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,510,000.00 Net Margins-13.31% Pretax MarginN/A Return on Equity-52.36% Return on Assets5.18% Debt Debt-to-Equity Ratio17.23 Current Ratio1.54 Quick Ratio3.00 Sales & Book Value Annual Sales$356.88 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow8.35 Book ValueA$0.24 per share Price / BookN/AMiscellaneous Outstanding Shares323,400,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.42 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Christian P. Behrenbruch BEng(Hons) (Age 48)DPhil(Oxon), GAICD, J.D., M.B.A., MBA, Co-Founder, MD, Group CEO & Executive Director Comp: $599.23kMr. Darren Smith B.Bus. (Age 58)FCPA, M.B.A., Group Chief Financial Officer Comp: $245.86kDr. Andreas Kluge M.D.Ph.D., Chief Medical Advisor & Director (Leave of Absence)Dr. Colin Hayward FFPMMBBS, Group Chief Medical OfficerMr. Richard Valeix M.B.A.Group Chief Commercial OfficerDr. Michael Wheatcroft B.Sc.BSc(Hons), Ph.D., Ph.D., (Cantab), Chief ScientistMr. Craig UlrickChief Information OfficerMs. Kyahn Williamson B.A.Senior Vice President of Corporate Communications & Investor RelationsMs. Melanie Farris (AGIAACG, ACIS) BComn, B.Com., GradDip, M.A.I.C., Senior VP of Global Governance, Risk & ComplianceMs. Lena Moran-Adams L.L.B.General CounselMore ExecutivesKey Competitors3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAbzenaLON:ABZAView All CompetitorsInsidersChristian BehrenbruchSold 120,268 sharesTotal: $356,714.89 ($2.97/share)Tiffany OlsonBought 51,305 shares on 3/16/2023Total: $343,384.37 ($6.69/share)Tiffany OlsonBought 10,930 shares on 12/12/2022Total: $73,252.86 ($6.70/share) TLX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Telix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Telix Pharmaceuticals investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS). This page (ASX:TLX) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.